Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Billing Codes · Pharmacy · Oncology, Hematology, Pediatrics +1 moreMedium impact

08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)

Act
by Jan 1, 2026
Effective date
Jan 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross reissued policy 08.01.35k on Rylaze® (asparaginase erwinia chrysanthemi recombinant-rywn) with no substantive changes, confirming coverage for ALL and lymphoblastic lymphoma in patients with E. coli asparaginase hypersensitivity. The HCPCS code J9019 (old Erwinaze formulation) has been terminated and removed; only J9021 (Rylaze) is now valid for billing.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jan 1, 2026 · 6 steps
01Billing team must update billing system to remove HCPCS code J9019 from all claim submission workflows and encounter forms.
02Ensure J9021 is the only valid asparaginase erwinia chrysanthemi code used.
03Any claims submitted with J9019 after the effective date will be denied.
04Verify that prior authorization processes require documentation of E.
05coli-derived asparaginase hypersensitivity and absence of documented contraindications (serious hypersensitivity to Rylaze, serious pancreatitis, hemorrhagic events/thrombosis, severe hepatic impairment) before approving J9021 claims.
06Update internal coding references and provider resources to reflect code termination.

Codes mentioned

J9019J9021

Original notice

08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)LowEffective Jan 1, 2026 · PharmacyMA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · Pharmacy08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · PharmacyMA08.085i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyHematologyPediatricsPharmacyCode J9019Code J9021

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account